^
    Back
    Association details:
    Biomarker:ABL1 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2018
    Title:

    Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

    Published date:
    11/01/2018
    Excerpt:
    A total of 10 (6 male & 4 female) patients were enrolled. Six patients were diagnosed as CML-MBP and 4 patients as AML-BCR/ABL1….CR was achieved in all (CR in 9 patients and CRi in 1) patients….In conclusion, nilotinib combined with IC is feasible and can be a good bridging therapy for these extremely rare CML-MBP or AML-BCR/ABL1 if they are IC-eligible...
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1182/blood-2018-99-116488